WuXi XDC Cayman Inc. Stock

Equities

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
19.06 USD +0.63% Intraday chart for WuXi XDC Cayman Inc. -17.31% -40.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2023 2.12B 294M Sales 2024 * 3.16B 437M Capitalization 20.62B 2.85B
Net income 2023 284M 39.31M Net income 2024 * 576M 79.73M EV / Sales 2023 16.1 x
Net cash position 2023 * 3.52B 487M Net cash position 2024 * 3.37B 466M EV / Sales 2024 * 5.46 x
P/E ratio 2023
112 x
P/E ratio 2024 *
36.1 x
Employees 1,178
Yield 2023 *
-
Yield 2024 *
-
Free-Float 15.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.63%
1 week-17.31%
Current month-12.97%
1 month-3.64%
3 months+30.19%
Current year-40.44%
More quotes
1 week
18.18
Extreme 18.18
21.90
1 month
16.50
Extreme 16.5
23.20
Current year
12.08
Extreme 12.08
33.10
1 year
12.08
Extreme 12.08
34.00
3 years
12.08
Extreme 12.08
34.00
5 years
12.08
Extreme 12.08
34.00
10 years
12.08
Extreme 12.08
34.00
More quotes
Date Price Change Volume
24-05-09 19.06 +0.63% 4 336 964
24-05-09 18.94 +2.82% 5,099,914
24-05-08 18.42 -6.31% 6,591,504
24-05-07 19.66 -5.93% 5,019,768
24-05-06 20.9 +1.21% 6,003,679

End-of-day quote Hong Kong S.E., May 09, 2024

More quotes
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
17.61 CNY
Average target price
28.8 CNY
Spread / Average Target
+63.53%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW